Peer-reviewed veterinary case report
Treatment options for resistant multicentric lymphoma in dogs
By Zimmerman, Kelley et al.·Published in Veterinary and comparative oncology·2023·Department of Clinical Science & Advanced Medicine, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Evaluation of mechlorethamine, vinblastine, procarbazine, and prednisone for the treatment of resistant multicentric canine lymphoma.
- Species:
- dog
Plain-English summary
A group of 36 dogs with relapsed lymphoma (a type of cancer) were treated with a modified chemotherapy protocol that replaced a common drug (vincristine) with vinblastine to see if it would be less harsh on their stomachs. The treatment led to a response in about 25% of the dogs, with an average time before the cancer progressed being 15 days and an average overall survival of 45 days. While the treatment provided only modest benefits, it was well tolerated, meaning the dogs did not experience severe side effects that required hospitalization. This suggests that increasing the dose might improve results in the future.
People also search for: dog lymphoma treatment options · vinblastine for dogs cancer · canine chemotherapy side effects
Abstract
Multi-agent chemotherapy successfully induces remission in most naïve, high-grade canine lymphoma patients; however, disease recurrence is common. MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) is an effective rescue protocol used to re-induce remission, but is associated with gastrointestinal toxicity and can be a less desirable option for patients that previously failed vincristine-containing protocols. Therefore, alternative members of the vinca alkaloid family, such as vinblastine, could be potentially advantageous as substitutes for vincristine to reduce gastrointestinal toxicity and chemoresistance. The objective of this study was to report the clinical outcomes and toxicity of 36 dogs with relapsed or refractory multicentric lymphoma treated with a modified MOPP protocol whereby vincristine was replaced with vinblastine (MVPP). The overall response rate to MVPP was 25% with a median progression free survival of 15 days and a median overall survival of 45 days. MVPP at the prescribed doses resulted in modest and transient clinical benefit, but was well tolerated with no treatment delays or hospitalizations secondary to side effects. Given the minimal toxicity, dose intensification could be considered to improve clinical responses.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/37222086/